Cefpodoxime is a third-generation cephalosporin antibiotic useful against many Gram-postitive and Gram-negative bacteria, including enteric bacteria and other eubacteria. However, cefpodoxime cannot be used to treat Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Cefpodoxime proxetil is an oral prodrug that becomes de-esterified into the cefpodoxime, the active metabolite.
Mechanism of action
Like other cephalosporins and peniciillins, cefpodoxime inhibits the proper formation of bacterial cells walls in the last stage of cell wall synthesis. Because cefpodoxime is stable against many beta-lactamases, many organisms that are resistant to penicillins and cephalosporins, due to their beta-lactamase production, may be susceptible to cefpodoxime. Some extended-spectrum beta-lactamases may inactivate cefpodoxime.
The systematic IUPAC chemical name for cefpodoxime is (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, and its chemical formula, C15H17N5O6S2, gives is a molecular mass of 427.4554 g/mol. Like other cephalosporins and the penicillins, cefpodoxime contains a beta-lactam as the active functional group, subject to ring opening and irreversible binding via acylation to penicillin binding proteins 1A/1B.
Patients with known allergies to penicillins or other cephalosporins should not take cefpodoxime, as this may result in a serious allergic reaction. Contact a physician immediately if any of the follow symptoms occur: hives, itching, skin rash, sore throat or mouth, swallowing or breathing difficulties, such as wheezing, or a vaginal infection. Take should be taken when using this drug in combination with anticoagulants.
The most up-to-date information about Cefpodoxime and other drugs can be found at the following sites.